These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20041957)

  • 1. An improved manufacturing process for Xyntha/ReFacto AF.
    Kelley B; Jankowski M; Booth J
    Haemophilia; 2010 Sep; 16(5):717-25. PubMed ID: 20041957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
    Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
    Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production processes of licensed recombinant factor VIII preparations.
    Boedeker BG
    Semin Thromb Hemost; 2001 Aug; 27(4):385-94. PubMed ID: 11547361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmissible spongiform encephalopathy agent clearance by the immunoaffinity and anion-exchange chromatography steps of the ReFacto manufacturing process.
    Booth J; Vicik S; Tannatt M; Gallo C; Kelley B
    Haemophilia; 2007 Sep; 13(5):580-7. PubMed ID: 17880447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration.
    Nowak T; Popp B; Gröner A; Schäfer W; Kalina U; Enssle K; Roth NJ
    Transfusion; 2017 May; 57(5):1184-1191. PubMed ID: 28191640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII.
    Roberts PL; Dunkerley C; McAuley A; Winkelman L
    Vox Sang; 2007 Jan; 92(1):56-63. PubMed ID: 17181591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removal and inactivation of hepatitis B virus from contaminated pooled plasma in a large-scale manufacturing process for factor VIII and human serum albumin.
    Murozuka T; Aoki M; Kimura N; Sotoyama K; Abe I; Izumi H; Emura H; Takeda Y; Nanakawa H; Katsubayashi Y; Takeuchi T; Ito H; Hirakawa S; Mitsunaga S; Tadokoro K; Kanemitsu K; Miyamoto M; Yamanaka R; Nishioka K
    Vox Sang; 1999; 76(3):181-6. PubMed ID: 10341335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Removal of viral contaminants by monoclonal antibody purification of plasma proteins.
    Schreiber AB; Hrinda ME; Newman J; Tarr GC; D'Alisa R; Curry WM
    Curr Stud Hematol Blood Transfus; 1989; (56):146-53. PubMed ID: 2491983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of an affinity chromatography step using a peptide ligand for cGMP production of factor VIII.
    Kelley BD; Tannatt M; Magnusson R; Hagelberg S; Booth J
    Biotechnol Bioeng; 2004 Aug; 87(3):400-12. PubMed ID: 15281114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive immunogenicity of Refacto AF.
    Delignat S; Repessé Y; Gilardin L; Dimitrov JD; Lone YC; Kaveri SV; Lacroix-Desmazes S
    Haemophilia; 2014 Jul; 20(4):486-92. PubMed ID: 24372710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein.
    McCue J; Kshirsagar R; Selvitelli K; Lu Q; Zhang M; Mei B; Peters R; Pierce GF; Dumont J; Raso S; Reichert H
    Biologicals; 2015 Jul; 43(4):213-9. PubMed ID: 26094124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq®), a new generation recombinant factor VIII produced in a human cell-line.
    Winge S; Yderland L; Kannicht C; Hermans P; Adema S; Schmidt T; Gilljam G; Linhult M; Tiemeyer M; Belyanskaya L; Walter O
    Protein Expr Purif; 2015 Nov; 115():165-75. PubMed ID: 26318235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BAY 81-8973, a full-length recombinant factor VIII: manufacturing processes and product characteristics.
    Garger S; Severs J; Regan L; Hesslein A; Ignowski J; Wu P; Long E; Gupta S; Liu S; Wang W
    Haemophilia; 2017 Mar; 23(2):e67-e78. PubMed ID: 27995680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogen safety of human C1 esterase inhibitor concentrate.
    Gröner A; Nowak T; Schäfer W
    Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
    Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
    J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral safety of B-domain deleted recombinant factor VIII.
    Charlebois TS; O'connell BD; Adamson SR; Brink-Nilsson H; Jernberg M; Eriksson B; Kelley BD
    Semin Hematol; 2001 Apr; 38(2 Suppl 4):32-9. PubMed ID: 11449333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
    Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
    Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous and semi-continuous cell culture for production of blood clotting factors.
    Desai SG
    J Biotechnol; 2015 Nov; 213():20-7. PubMed ID: 25738489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogen safety of Beriate®.
    Gröner A
    Thromb Res; 2014 Nov; 134 Suppl 1():S10-5. PubMed ID: 24726555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.